Related Experiment Videos
Ginseng-derived cholesterol analogues enhance pulmonary siRNA delivery and alleviate allergic asthma
Liangkun Xie1, Wenliang Sun1, Xiaotong Jiang1
1Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No 103, 110016 Shenyang, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, 110016 Shenyang, China.
Background:
Asthma patients exhibit elevated airway mucus secretion. Small interfering RNA (siRNA) targeting the mucin MUC5AC delivered by lipid nanoparticles (LNPs) is promising but limited by low transfection efficiency. Protopanaxadiol (PPD), protopanaxatriol (PPT), and ginsenoside Rh2 (GR2) were chosen because their dammarane skeleton preserves membrane-insertion capacity for endosomal escape, whereas bulkier multi-glycosylated ginsenosides adversely affect LNP size and stability.
Purpose:
In this study, we designed novel inhaled LNPs incorporating ginseng-derived cholesterol analogs to enhance therapeutic efficacy against asthma.
Methods:
PPD and PPT were used as membrane components to formulate anti-MUC5AC siRNA-loaded LNPs (designated as DLNPs and TLNPs). Flow cytometry and confocal laser scanning microscopy (CLSM) were employed to evaluate the cellular uptake and lysosomal escape of LNPs. An asthmatic mouse model was established to assess therapeutic effects of DLNPs and TLNPs through pathological section analysis and determination of inflammatory cytokine levels.
Results:
The data showed that these novel formulations enhanced cellular uptake by airway epithelial cells (AECs) and promoted siRNA escape from lysosomes, thereby improving pulmonary delivery efficiency. TLNPs, in particular, demonstrated superior performance. Furthermore, DLNPs and TLNPs exerted multifaceted anti‑asthmatic effects in vivo, as evidenced by significant suppression of MUC5AC overexpression in AECs, attenuation of inflammatory cell infiltration, and reduction in the secretion of the critical cytokines IL‑4 and IL‑13.
Conclusion:
Overall, our findings indicate that ginseng-derived PPD and PPT effectively enhance siRNA delivery and mitigate asthma symptoms through dual inhibition of MUC5AC overexpression and airway inflammation. These cholesterol analogs represent promising carrier materials for LNP-based pulmonary therapeutics.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...